Precision Business Insights
Portfolio

 

Sarcoidosis Drugs Market

: Global Market Estimation, Dynamics, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

Global Sarcoidosis Drugs Market: By Product Type (Tumor Necrosis Factor Alpha (TNF-α) Inhibitors, Corticosteroids, Immunosuppressant Drugs, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

Global Sarcoidosis Drugs Market

 

Market Outline: Global Sarcoidosis Drugs Market

Sarcoidosis is the disease characterized by growth of tiny collections of inflammatory cells in various parts of the body such as lungs, skin, eyes, lymph nodes, nervous system, and glands among others. The signs and symptoms of the sarcoidosis is depend on the type of organ affected. However, the general symptoms associated with the disease include fever, fatigue, weight loss, and swollen lymph nodes. The exact cause for the disease is unknown however, it may appear to have genetic predisposition to develop the disease, which may be triggered by bacteria, viruses, dust or chemicals.

 

Market Dynamics: Global Sarcoidosis Drugs Market

Increase in the prevalence of sarcoidosis due to bacterial and viral infections drives the global sarcoidosis drugs market. Moreover, raise in funding by public and private sectors for the development of newer drugs, technological advancements for the disease diagnosis, strong product pipeline for the sarcoidosis treatment, and increase in healthcare expenditure are surge global sarcoidosis drugs market over the forecast years. However, stringent regulations for product approval, adverse effects associated with the drugs, and poor disease awareness in underdeveloped countries are impede the growth of global sarcoidosis drugs market.

 

Market Scope: Global Sarcoidosis Drugs Market

Global sarcoidosis drugs market is segmented based on drug class, route of administration, and distribution channel

Based on drug class, market is segmented into the following:

  • Tumor Necrosis Factor Alpha (TNF-α) Inhibitors
  • Corticosteroids
  • Immunosuppressant Drugs
  • Others

Based on route of administration, market is segmented into the following:

  • Oral
  • Parenteral
  • Others

Geography

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Based on the distribution channel, market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Analysis: Global Sarcoidosis Drugs Market

Geographically, global sarcoidosis drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America sarcoidosis drugs market is poised to grow due to rise in prevalence of sarcoidosis disease, collaboration between the industries and academics for the R&D activities, raise in funding from government are bolster the market. Europe sarcoidosis drugs market is driving by rise in adoption of newer therapeutics, promising pipeline drugs for the sarcoidosis treatment, and sophisticated healthcare infrastructure for the early stage disease diagnosis are surge the market. Asia Pacific sarcoidosis drugs market has prominent share attributed to rise in awareness about the sarcoidosis treatment, grow in healthcare expenditure, and entry of market players into Asia Pacific region are fuel the market.

 

Competition Assessment: Global Sarcoidosis Drugs Market

Some of the players in the global sarcoidosis drugs market include:

  • Novartis AG (Switzerland)
  • Merck & Co., Inc., (U.S)
  • Advenchen Laboratories, LLC (U.S)
  • EpiZyme, Inc. (U.S.)
  • Araim Pharmaceuticals, Inc. (U.S.)
  • Relief Therapeutics Holding SA (Switzerland)
  • Adaptimmune Therapeutics (U.K.)
  • Bellus Health, Inc. (Canada)
  • Firststring Research, Inc. (U.S.)
  • PharmaIN Corporation (U.S.)

Notable Market Developments: Global Sarcoidosis Drugs Market

  • In July 2016, Araim Pharnaceuticals announced that its lead candidate, Innate Repair Receptor (IRR) activator ARA 290, has been designed an orphan drug for the treatment of sarcoidosis by the U.S. Food and Drug Administration (FDA)
    
$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials